1 month ago

Biocon Gets Canada Approval for Yesintek Autoinjector

Biocon Gets Canada Approval for Yesintek Autoinjector
Biocon gets Canada government’s nod for Yesintek autoinjector to treat autoimmune diseases · financialexpress.com

Biocon, a big medicine company from India, just got permission from Canada to sell a new autoinjector called Yesintek.

This autoinjector helps people with diseases like psoriasis and Crohn's disease.

It's a big deal because it gives patients another way to get their medicine, and it shows Biocon is serious about helping people around the world.

The company has been around for a long time and sells medicines in lots of countries.

Even though their stock went down a little today, it has gone up a lot in the last few months.

Key facts

Company
Biocon
Approval
Notice of Compliance (NOC) from Health Canada
Product
Yesintek (ustekinumab) Autoinjector
Strengths
45 mg/0.5 mL and 90 mg/mL
Indications
Plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis
Headquarters
Bengaluru, India
Founded
1978
Market Presence
More than 120 countries

Sources

Related news